FDA OKs Drug Combo in BRAF V600E-Mutated Metastatic NSCLC FDA OKs Drug Combo in BRAF V600E-Mutated Metastatic NSCLC

The single-arm approval study reported an objective response rate of 75% among treatment-naive patients.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news